The STAT report highlights Tippi MacKenzie's decades-long pursuit of fetal gene therapy, now with an IND application for five patients with lysosomal storage disorders, bypassing further animal tests due to established AAV vector safety data. Yet this overlooks critical gaps: while mouse models from the early 2000s showed cures for hemophilia and tyrosinemia, human translation demands scrutiny of long-term off-target effects not captured in short-term adult trials. An observational study in Nature Medicine (2019, n=12 non-human primates) demonstrated AAV9 vector persistence in fetal tissues with minimal immunogenicity, but lacked randomization and had industry funding from Spark Therapeutics, raising conflict concerns. Synthesizing this with a 2022 Lancet review of 45 postnatal gene therapy cases (mostly observational, small samples under 50), the upcoming trial could prevent irreversible damage in conditions like mucopolysaccharidosis, but ethical oversight for consent in pregnant patients remains underexplored. MacKenzie's approach marks proactive intervention over postnatal reactive care, yet underestimates potential mosaicism risks if editing efficiency varies across fetal organs.